Email this article 
Hide
Show all
Original Research
Dosage of sugammadex according to the calculated lean body mass in obese female patients: time to reverse moderate neuromuscular blockade induced by rocuronium
Southern African Journal of Anaesthesia and Analgesia | Vol 25, No 1 | a855 |
DOI: https://doi.org/10.1080/22201181.2019.1571719
| © 2019 Cheik Tidiane Hafid Wind-Pouiré Bougouma, Jean-Luc R.J. Demeere
| This work is licensed under Other
Submitted: 05 November 2025 | Published: 30 January 2019
Submitted: 05 November 2025 | Published: 30 January 2019
About the author(s)
Cheik Tidiane Hafid Wind-Pouiré Bougouma, Department of Anaesthesiology and Intensive Care, Blaise Compaore Hospital, Tingandogo, Burkina Faso; and, Department of Anaesthesiology, Saint-Jean Hospital, Brussels, BelgiumJean-Luc R.J. Demeere, Department of Anaesthesiology, Saint-Jean Hospital, Brussels, Belgium
Full Text:
PDF (360KB)Abstract
Background: Sugammadex is a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular blockade. The recommended dose is 2 mg/kg. Based on the pharmacological characteristics of sugammadex in obese patients, the calculated lean body mass (CLBM) should be used to determine the dose to reverse moderate neuromuscular blockade induced by rocuronium.
Objective: A study was undertaken to prove that sugammadex can be used according to CLBM to reverse moderate neuromuscular blockade in obese female patients.
Methods: This is a prospective, non-randomised, observational study. Sugammadex was used at the end of bariatric surgery on obese patients with a body mass index > 32 kg/m2. The dose was calculated according to the lean body mass. Muscle blockade was assessed using train-of-four monitoring.
Results: Twenty women were included in this study. All patients were female and ASA 2. The age of patients ranged between 20 and 50 years with a mean age of 35.74 (±10) years. The mean CLBM was 50 kg. The mean time from administration of sugammadex to reverse neuromuscular blockade from two responses of TOF to T4/T1 > 90% was 167.25 seconds (2.8 minutes) (60–285 seconds).
Conclusion: It is concluded that the calculated lean body mass can be used to calculate the dose of sugammadex for obese female patients to reverse moderate neuromuscular blockade induced by rocuronium.
Objective: A study was undertaken to prove that sugammadex can be used according to CLBM to reverse moderate neuromuscular blockade in obese female patients.
Methods: This is a prospective, non-randomised, observational study. Sugammadex was used at the end of bariatric surgery on obese patients with a body mass index > 32 kg/m2. The dose was calculated according to the lean body mass. Muscle blockade was assessed using train-of-four monitoring.
Results: Twenty women were included in this study. All patients were female and ASA 2. The age of patients ranged between 20 and 50 years with a mean age of 35.74 (±10) years. The mean CLBM was 50 kg. The mean time from administration of sugammadex to reverse neuromuscular blockade from two responses of TOF to T4/T1 > 90% was 167.25 seconds (2.8 minutes) (60–285 seconds).
Conclusion: It is concluded that the calculated lean body mass can be used to calculate the dose of sugammadex for obese female patients to reverse moderate neuromuscular blockade induced by rocuronium.
Keywords
calculated lean body mass; neuromuscular blockade; rocuronium; sugammadex
Metrics
Total abstract views: 499Total article views: 97